Last updated on March 2020

A Study of Ibrutinib in Combination With Rituximab in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Brief description of study

The purpose of this study is to evaluate overall response rate (ORR) by Independent Review Committee (IRC) assessment, when combined with rituximab in Japanese participants with treatment nave or relapsed/refractory Waldenstrom's Macroglobulinemia (WM).

Clinical Study Identifier: NCT04062448

Find a site near you

Start Over

NHO Disaster Medical Center

Tachikawa, Japan
  Connect »